Состав:
Применение:
Применяется при лечении:
Артралгия,Болезненная менструация,Боли в спине,Боль,Боль в горле,Боль в ухе,Головная боль,Грипп,Зубная боль,Лихорадка,Мигрень,Мышечные Боли,Напряженная головная боль,Невралгия,Простуда,Синдром Прорезывания Зубов
Страница осмотрена фармацевтом Федорченко Ольгой Валерьевной Последнее обновление 2022-04-06
Внимание!
Информация на странице предназначена только для медицинских работников!
Информация собрана в открытых источниках и может содержать значимые ошибки!
Будьте внимательны и перепроверяйте всю информацию с этой страницы!
Топ 20 лекарств с такими-же компонентами:
Топ 20 лекарств с таким-же применением:
Предоставленная в разделе Deponинформация составлена на основе данных о другом лекарстве с точно таким же составом как лекарство Depon. Будьте
внимательны и обязательно уточняйте информацию по разделу в инструкции к лекарству Depon непосредственно из упаковки или у фармацевта в аптеке.
more…
Depon
Предоставленная в разделе Deponинформация составлена на основе данных о другом лекарстве с точно таким же составом как лекарство Depon. Будьте
внимательны и обязательно уточняйте информацию по разделу в инструкции к лекарству Depon непосредственно из упаковки или у фармацевта в аптеке.
more…
Acetaminophen
Предоставленная в разделе Deponинформация составлена на основе данных о другом лекарстве с точно таким же составом как лекарство Depon. Будьте
внимательны и обязательно уточняйте информацию по разделу в инструкции к лекарству Depon непосредственно из упаковки или у фармацевта в аптеке.
more…
Суспензия для приема внутрь
Таблетки
У детей с 3 мес (от 1 до 3 мес применение Deponа по всем показаниям возможно только по назначению врача) до 6 лет в качестве жаропонижающего средства (ОРВИ, грипп, детские инфекции, поствакцинальные реакции и другие состояния, сопровождающиеся повышенной температурой тела) и болеутоляющего средства (болевой синдром слабой и умеренной интенсивности, в т.ч. головная и зубная боль, боль в мышцах, невралгия, боль при травмах и ожогах).
Болевой синдром слабой или умеренной интенсивности (головная боль, невралгия, миалгия, артралгия, альгодисменорея, зубная боль), понижение повышенной температуры тела при инфекционно-воспалительных заболеваниях (в т.ч. простудных).
Предоставленная в разделе Deponинформация составлена на основе данных о другом лекарстве с точно таким же составом как лекарство Depon. Будьте
внимательны и обязательно уточняйте информацию по разделу в инструкции к лекарству Depon непосредственно из упаковки или у фармацевта в аптеке.
more…
Драже; Суспензия для приема внутрь для детей
Суспензия для приема внутрь
Таблетки
Внутрь. Взрослым по 500 мг до 4 раз в сутки, максимальная разовая доза — 1 г, суточная — 4 г. Курс не более 5 дней. Детям по 10–15 мг/кг каждые 6 ч, курс 3–5 дней.
Внутрь, запивая большим количеством жидкости, через 1–2 ч после приема пищи 3–4 раза в сутки с интервалом не менее 4 ч.
Суспензию Depon для детей не следует разводить. Для удобства и точности дозирования используют мерную ложку, отмеряющую 2,5 и 5 мл суспензии.
Рекомендуемые дозы для детей от 3 мес до 6 лет
| Возраст | Разовые дозы |
| 3 мес — 1 год | 60–120 мг парацетамола (2,5–5 мл) |
| От 1 года до 6 лет | 120–240 мг парацетамола (5–10 мл) |
Продолжительность лечения: 3 дня в качестве жаропонижающего и до 5 дней в качестве болеутоляющего средства. При необходимости продолжения приема препарата требуется консультация врача.
Внутрь, предпочтительнее между приемами пищи, шипучую таблетку полностью растворяют в стакане воды, а полученный раствор сразу выпивают. Если врачом не даны другие указания, то при применении препарата следует соблюдать следующие дозировки:
взрослые: по 500–1000 мг (1–2 шипучие таблетки) 3–4 раза в сутки, максимальная доза — 4 г/сут.
дети: дозировка по массе тела ребенка подразумевает прием дозы 10–15 мг/кг. Удобная схема дозировок приведена в таблице.
| Возраст | Масса тела, кг | Разовая доза, мг | Максимальная суточная доза, г |
| 6–9 лет | 22–30 | 250 (0,5 табл.) | 1–1,5 (2–3 табл.) |
| 9–12 лет | до 40 | 500 (1 табл.) | 2 (4 табл.) |
| старше 12 лет | >40 | 500–1000 (1–2 шипучих табл.) | 2–4 (4–8 табл.) |
Рекомендуемый интервал между приемами — 6–8 ч (не менее 4 ч). Максимальная продолжительность лечения для детей — 3 дня, для взрослых — не более 5 дней при назначении в качестве обезболивающего средства и не более 3 дней при назначении в качестве жаропонижающего средства. После 5 дней лечения проводят анализ периферической крови.
Предоставленная в разделе Deponинформация составлена на основе данных о другом лекарстве с точно таким же составом как лекарство Depon. Будьте
внимательны и обязательно уточняйте информацию по разделу в инструкции к лекарству Depon непосредственно из упаковки или у фармацевта в аптеке.
more…
Суспензия для приема внутрь
Таблетки
Гиперчувствительность, тяжелые нарушения функции печени, почек, заболевания крови, дефицит глюкозо-6-фосфатдегидрогеназы, грудной возраст до 1 мес.
Повышенная чувствительность к компонентам препарата, почечная и печеночная недостаточность, дефицит глюкозо−6-фосфатдегидрогеназы, беременность, кормление грудью, детский возраст до 6 лет.
Предоставленная в разделе Deponинформация составлена на основе данных о другом лекарстве с точно таким же составом как лекарство Depon. Будьте
внимательны и обязательно уточняйте информацию по разделу в инструкции к лекарству Depon непосредственно из упаковки или у фармацевта в аптеке.
more…
Суспензия для приема внутрь
Таблетки
Тошнота, рвота, боли в животе, аллергические реакции (кожная сыпь, зуд, крапивница, отек Квинке); редко — тромбоцитопения, агранулоцитоз, лейкопения, анемия; при длительном применении в больших дозах — гепатотоксическое и нефротоксическое действие, панцитопения, метгемоглобинемия.
Аллергические реакции — кожная сыпь, зуд, крапивница, отек Квинке; тошнота, боль в эпигастрии; анемия, тромбоцитопения. При длительном применении в больших дозах — гепатотоксическое действие, нефротоксическое действие (почечная колика, асептическая пиурия, интерстициальный нефрит, папиллярный некроз), гемолитическая анемия, апластическая анемия, метгемоглобинемия, панцитопения, агранулоцитоз. Очень редко — понижение АД, гипогликемия, диспноэ, васкулит.
Предоставленная в разделе Deponинформация составлена на основе данных о другом лекарстве с точно таким же составом как лекарство Depon. Будьте
внимательны и обязательно уточняйте информацию по разделу в инструкции к лекарству Depon непосредственно из упаковки или у фармацевта в аптеке.
more…
Суспензия для приема внутрь
Таблетки
Симптомы: бледность, потливость, боль в желудке, тошнота и рвота, через 1–2 сут — признаки поражения печени (болезненность в области печени, повышение активности печеночных ферментов в крови, увеличение протромбинового времени). В тяжелых случаях — печеночная недостаточность, гепатонекроз, энцефалопатия, коматозное состояние.
Лечение: прекращение приема препарата, промывание желудка, назначение энтеросорбентов (активированный уголь, полифепан), в/в введение антидота — N-ацетилцистеина или назначение внутрь метионина.
Симптомы: бледность кожных покровов, анорексия, тошнота, рвота; гепатонекроз (выраженность некроза вследствие интоксикации прямо зависит от степени передозировки).
Лечение: промывание желудка, назначение активированного угля.
Предоставленная в разделе Deponинформация составлена на основе данных о другом лекарстве с точно таким же составом как лекарство Depon. Будьте
внимательны и обязательно уточняйте информацию по разделу в инструкции к лекарству Depon непосредственно из упаковки или у фармацевта в аптеке.
more…
Обладает чрезвычайно малым влиянием на синтез ПГ в периферических тканях, не изменяет водно-солевой обмен (задержка натрия и воды) и не повреждает слизистую ЖКТ.
Предоставленная в разделе Deponинформация составлена на основе данных о другом лекарстве с точно таким же составом как лекарство Depon. Будьте
внимательны и обязательно уточняйте информацию по разделу в инструкции к лекарству Depon непосредственно из упаковки или у фармацевта в аптеке.
more…
Суспензия для приема внутрь
Таблетки
Cmax в плазме достигается через 30–90 мин после приема внутрь. Величина соотношения объема распределения и биодоступности у детей и новорожденных подобна таковым у взрослых. T1/2 — 1,5–2,5 ч. Метаболизируется в печени. У новорожденных и детей до 10 лет основным метаболитом является сульфат парацетамола, у детей 12 лет и старше — конъюгированный глюкуронид. При недостатке глутатиона эти метаболиты могут блокировать ферментные системы гепатоцитов и вызывать их некроз. Примерно 85–95% дозы выводится с мочой за 24 ч (менее 4% препарата — в неизмененном виде).
Абсорбция высокая, связывание с белками плазмы — 15%. Cmax в плазме достигается через 0,5–2 ч. Проходит через ГЭБ, проникает в грудное молоко (менее 1% от принятой дозы). Эффективная терапевтическая концентрация в плазме достигается при назначении в дозе 10–15 мг/кг.
Метаболизируется в печени: 80% конъюгирует с глюкуроновой кислотой и сульфатами с образованием неактивных метаболитов, 17% гидроксилируется с образованием активных метаболитов, которые конъюгируют с глутатионом и образуют неактивные метаболиты. При недостатке глутатиона эти метаболиты могут блокировать ферментные системы гепатоцитов и вызывать их некроз. Т1/2 — 2–3 ч, у пожилых пациентов клиренс препарата снижается и увеличивается период полувыведения. Выводится почками — 3% в неизмененном виде.
Фармокологическая группа
Предоставленная в разделе Фармокологическая группа Deponинформация составлена на основе данных о другом лекарстве с точно таким же составом как лекарство Depon. Будьте
внимательны и обязательно уточняйте информацию по разделу Фармокологическая группа
в инструкции к лекарству Depon непосредственно из упаковки или у фармацевта в аптеке.
more…
- Анилиды
Взаимодействие
Предоставленная в разделе Взаимодействие Deponинформация составлена на основе данных о другом лекарстве с точно таким же составом как лекарство Depon. Будьте
внимательны и обязательно уточняйте информацию по разделу Взаимодействие
в инструкции к лекарству Depon непосредственно из упаковки или у фармацевта в аптеке.
more…
Суспензия для приема внутрь
Таблетки
Алкоголь, барбитураты, трициклические антидепрессанты, противосудорожные препараты, фенилбутазон, рифампицин усиливают гепатотоксичность, салицилаты — нефротоксическое действие.
Парацетамол усиливает действие непрямых антикоагулянтов, снижает эффективность урикозурических препаратов, повышает токсичность хлорамфеникола.
Стимуляторы микросомального окисления в печени (фенитоин, этанол, барбитураты, рифампицин, фенилбутазон, трициклические антидепрессанты, эстрогенсодержащие контрацептивы) увеличивают продукцию гидроксилированных активных метаболитов, что обусловливает возможность развития тяжелых интоксикаций при небольших передозировках. Этанол способствует развитию острого панкреатита. Ингибиторы микросомального окисления (циметидин) снижают риск гепатотоксического действия. Снижает эффективность урикозурических препаратов. Усиливает действие препаратов, угнетающих ЦНС, этанола. При замедлении опорожнения желудка (пропантелин) может иметь место замедленное наступление действия парацетамола, а при ускорении (метоклопрамид) — препарат начинает действовать быстрее. Усиливается токсичность хлорамфеникола. Следует соблюдать осторожность при продолжительном применении парацетамола и одновременной терапии пероральными препаратами, тормозящими свертывание крови.
Depon цена
У нас нет точных данных по стоимости лекарства.
Однако мы предоставим данные по каждому действующему веществу
Средняя стоимость Acetaminophen 500 mg за единицу в онлайн аптеках от 0.16$ до 0.31$, за упаковку от 21$ до 31$.
Средняя стоимость Acetaminophen 120 mg за единицу в онлайн аптеках от 2.05$ до 2.05$, за упаковку от 25$ до 25$.
Средняя стоимость Acetaminophen 325 mg за единицу в онлайн аптеках от 0.21$ до 0.21$, за упаковку от 21$ до 21$.
Средняя стоимость Acetaminophen 650 mg за единицу в онлайн аптеках от 2.3$ до 2.3$, за упаковку от 28$ до 28$.
Источники:
- https://www.drugs.com/search.php?searchterm=depon
- https://pubmed.ncbi.nlm.nih.gov/?term=depon
Доступно в странах
Найти в стране:
А
Б
В
Г
Д
Е
З
И
Й
К
Л
М
Н
О
П
Р
С
Т
У
Ф
Х
Ч
Ш
Э
Ю
Я
Top 20 medicines with the same components:
Top 20 medicines with the same treatments:
The information provided in of Depon
is based on data of another medicine with exactly the same composition as the Depon.
. Be careful and be sure to specify the information on the section in the instructions to the drug Depon directly from the package or from the pharmacist at the pharmacy.
more…
Depon
The information provided in of Depon
is based on data of another medicine with exactly the same composition as the Depon.
. Be careful and be sure to specify the information on the section in the instructions to the drug Depon directly from the package or from the pharmacist at the pharmacy.
more…
Acetaminophen
The information provided in of Depon
is based on data of another medicine with exactly the same composition as the Depon.
. Be careful and be sure to specify the information on the section in the instructions to the drug Depon directly from the package or from the pharmacist at the pharmacy.
more…
Pills; Rectal suppositories; Rectal suppositories for children; Solution for infusion; Substance; Substance-powder; Syrup; Tablets, effervescent
Bolus; Coated tablet; Effervescent tablet; Film-coated tablet; Tablets, soluble
Suspension for ingestion for children
For the treatment of mild to moderate pain including headache, migraine, neuralgia, toothache, sore throat, period pains, aches and pains, symptomatic relief of rheumatic aches and pains and of influenza, feverishness and feverish colds.
Depon ActiFast is a mild analgesic and antipyretic, and is recommended for the treatment of most painful and febrile conditions, for example, headache including migraine and tension headaches, toothache, backache, rheumatic and muscle pains, dysmenorrhoea, sore throat, and for relieving the fever, aches and pains of colds and flu.
Depon Infant Sugar Free Colour Free 120 mg/5 ml Oral Suspension is indicated for the treatment of mild to moderate pain and as an antipyretic. It can be used in many conditions including headache, toothache, earache, teething, sore throat, colds and influenza, aches and pains and post-immunisation fever.
The information provided in of Depon
is based on data of another medicine with exactly the same composition as the Depon.
. Be careful and be sure to specify the information on the section in the instructions to the drug Depon directly from the package or from the pharmacist at the pharmacy.
more…
Pills; Rectal suppositories; Rectal suppositories for children; Solution for infusion; Substance; Substance-powder; Syrup; Tablets, effervescent
Bolus; Coated tablet; Effervescent tablet; Film-coated tablet; Tablets, soluble
Suspension for ingestion for children
Adults, the elderly and young persons 16 years and over:
2 tablets every 4 hours to a maximum of 8 tablets in 24 hours.
Children 6 — 9 years:
½ tablet every 4 hours to a maximum of 4 doses in 24 hours.
Children 10 — 11 years:
1 tablet every 4 hours to a maximum of 4 doses in 24 hours
Adolescents 12 — 15 years:
1 to 1 ½ tablets every 4 hours to a maximum of 4 doses in 24 hours
Do not give to children aged under 6 years of age.
For oral administration.
Adults, including the elderly and children 16 years and over:
Two tablets to be taken with half a tumbler of water (100 ml).
To ensure fast onset of pain relief no less than two tablets must be taken with 100 ml of water. For maximum speed of action this should be on an empty stomach.
Two tablets up to four times daily as required. The dose should not be repeated more frequently than every four hours nor should more than four doses be taken in any 24 hour period.
Children aged 12-15 years:
One tablet to be taken with half a tumbler of water (100ml), up to four times daily as required. The dose should not be repeated more frequently than every four hours nor should more than 4 doses be given in any 24 hour period.
Children under 12 years of age:
Depon ActiFast is not recommended for children under 12 years of age.
For the relief of fever after vaccinations at 2, 3 and 4 months
2.5ml. This dose may be given up to 4 times a day starting at the time of vaccination. Do not give more than 4 doses in any 24 hour period. Leave at least 4 hours between doses. If your baby still needs this medicine two days after receiving the vaccine talk to your doctor or pharmacist.
|
Age : 2 — 3 months |
Dose |
|
Pain and other causes of fever — if your baby weighs over 4 kg and was born after 37 weeks |
2.5 ml If necessary, after 4-6 hours, give a second 2.5 ml dose |
|
— Do not give to babies less than 2 months of age. — Leave at least 4 hours between doses. — Do not give more than 2 doses. This is to ensure that fever that may be due to a serious infection is quickly diagnosed. If your child is still feverish after two doses, talk to your doctor or pharmacist. |
Children aged 3 months — 6 years:
|
Child’s Age |
How Much |
How often (in 24 hours) |
|
3 — 6 months |
2.5 ml |
4 times |
|
6 — 24 months |
5 ml |
4 times |
|
2 — 4 years |
7.5 ml (5 ml + 2.5 ml) |
4 times |
|
4 — 6 years |
10 ml (5 ml + 5 ml) |
4 times |
|
— Do not give more than 4 doses in any 24 hour period — Leave at least 4 hours between doses — Do not give this medicine to your child for more than 3 days without speaking to your doctor or pharmacist |
It is important to shake the bottle for at least 10 seconds before use.
The Elderly:
In the elderly, the rate and extent of paracetamol absorption is normal but plasma half-life is longer and paracetamol clearance is lower than in young adults.
The information provided in of Depon
is based on data of another medicine with exactly the same composition as the Depon.
. Be careful and be sure to specify the information on the section in the instructions to the drug Depon directly from the package or from the pharmacist at the pharmacy.
more…
Pills; Rectal suppositories; Rectal suppositories for children; Solution for infusion; Substance; Substance-powder; Syrup; Tablets, effervescent
Bolus; Coated tablet; Effervescent tablet; Film-coated tablet; Tablets, soluble
Suspension for ingestion for children
Hypersensitivity to Depon or any of the constituents.
Hypersensitivity to paracetamol or any of the other constituents.
The information provided in of Depon
is based on data of another medicine with exactly the same composition as the Depon.
. Be careful and be sure to specify the information on the section in the instructions to the drug Depon directly from the package or from the pharmacist at the pharmacy.
more…
Pills; Rectal suppositories; Rectal suppositories for children; Solution for infusion; Substance; Substance-powder; Syrup; Tablets, effervescent
Bolus; Coated tablet; Effervescent tablet; Film-coated tablet; Tablets, soluble
Suspension for ingestion for children
Care is advised in the administration of Depon to patients with severe renal or severe hepatic impairment. The hazards of overdose are greater in those with non-cirrhotic alcoholic liver disease.
Do not take more medicine than the label tells you to. If you do not get better, talk to your doctor.
Contains Depon.
Do not take anything else containing Depon while taking this medicine.
Talk to your doctor at once if you take too much of this medicine, even if you feel well. This is because too much Depon can cause delayed, serious liver damage.
Patients should be advised that Depon may cause severe skin reactions. If a skin reaction such as skin reddening, blisters, or rash occurs, they should stop use and seek medical assistance right away.
Care is advised in the administration of paracetamol to patients with renal or hepatic impairment. The hazard of overdose is greater in those with non-cirrhotic alcoholic liver disease.
Do not exceed the stated dose.
Patients should be advised not to take other paracetamol-containing products concurrently.
Each Depon ActiFast tablet contains 173 mg of sodium and should not be taken by patients on a low sodium diet.
Patients should be advised to consult their doctor if their headaches become persistent.
If symptoms persist consult your doctor.
Keep out of the reach and sight of children.
Pack Label:
Immediate medical advice should be sought in the event of an overdose, even if you feel well.
Do not take with any other paracetamol-containing products.
Patient Information Leaflet:
Immediate medical advice should be sought in the event of an overdose, even if you feel well, because of the risk of delayed, serious liver damage.
Depon Infant Sugar Free Colour Free 120 mg/5 ml Oral Suspension should be used with caution in severe renal impairment or severe hepatic impairment. The hazards of overdose are greater in those with non-cirrhotic alcoholic liver disease.
Concomitant use of other paracetamol-containing products should be avoided.
Due to the presence of maltitol liquid (E965) and sorbitol liquid (E420), patients with rare hereditary problems of fructose intolerance should not take this medicine.
Ethyl (E214), Propyl (E216) and Methyl (E218) parahydroxybenzoate may cause allergic reactions (possibly delayed).
Patients should be informed about the signs of serious skin reactions, and use of the drug should be discontinued at the first appearance of skin rash or any other sign of hypersensitivity.
The label contains the following statements:
Contains paracetamol.
Do not give anything else containing paracetamol while giving this medicine.
Do not give more medicine than the label tells you to. If your child does not get better, talk to your doctor.
For oral use only.
Always use the syringe supplied with the pack.
Do not give to babies less than 2 months of age.
For infants 2-3 months no more than 2 doses should be given.
Do not give more than 4 doses in any 24 hour period.
Leave at least 4 hours between doses.
Do not give this medicine to your child for more than 3 days without speaking to your doctor or pharmacist.
As with all medicines, if your child is currently taking any other medicine consult your doctor or pharmacist before using this product.
Keep out of the sight and reach of children.
Do not store above 25°C. Keep bottle in the outer carton.
It is important to shake the bottle for at least 10 seconds before use.
Talk to a doctor at once if your child takes too much of this medicine, even if they seem well.
The leaflet contains the following statements:
Talk to a doctor at once if your child takes too much of this medicine, even if they seem well. This is because too much paracetamol can cause delayed, serious liver damage.
Talk to your doctor: If your child has an inherited intolerance to fructose or been diagnosed with an intolerance to some other sugars.
The sorbitol liquid (E420) and maltitol liquid (E965) content of this product means that this product is unsuitable for people with inherited intolerance to fructose.
Very rare cases of serious skin reactions have been reported. Symptoms may include:
— Skin reddening
— Blisters
— Rash
If skin reactions occur or existing skin symptoms worsen, stop use and seek medical help right away.
The information provided in of Depon
is based on data of another medicine with exactly the same composition as the Depon.
. Be careful and be sure to specify the information on the section in the instructions to the drug Depon directly from the package or from the pharmacist at the pharmacy.
more…
None.
The information provided in of Depon
is based on data of another medicine with exactly the same composition as the Depon.
. Be careful and be sure to specify the information on the section in the instructions to the drug Depon directly from the package or from the pharmacist at the pharmacy.
more…
Pills; Rectal suppositories; Rectal suppositories for children; Solution for infusion; Substance; Substance-powder; Syrup; Tablets, effervescent
Bolus; Coated tablet; Effervescent tablet; Film-coated tablet; Tablets, soluble
Suspension for ingestion for children
Adverse effects of Depon are rare. Very rare cases of serious skin reactions have been reported. There have been reports of blood dyscrasias including thrombocytopenia purpura, methaemoglobenaemia and agranulocytosis, but these were not necessarily causality related to Depon.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard.
Adverse events of paracetamol from historical clinical trial data are both infrequent and from small patient exposure. Accordingly, events reported from extensive post-marketing experience at therapeutic/labelled dose and considered attributable are tabulated below by system class. Due to limited clinical trial data, the frequency of these adverse events is not known (cannot be estimated from available data), but post-marketing experience indicates that adverse reactions to paracetamol are rare and serious reactions are very rare.
Post marketing data
|
Body System |
Undesirable effect |
|
Blood and lymphatic system disorders |
Thrombocytopenia Agranulocytosis |
|
Immune system disorders |
Anaphylaxis Cutaneous hypersensitivity reactions including skin rashes, angiodema and Stevens Johnson syndrome/toxic epidermal necrolysis |
|
Respiratory, thoracic and mediastinal disorders |
Bronchospasm* |
|
Hepatobiliary disorders |
Hepatic dysfunction |
* There have been cases of bronchospasm with paracetamol, but these are more likely in asthmatics sensitive to aspirin or other NSAIDs.
Adverse effects of paracetamol are rare but hypersensitivity/anaphylactic reactions including skin rash may occur. Very rare cases of serious skin reactions have been reported. There have been reports of blood dyscrasias including thrombocytopenia and agranulocytosis but these were not necessarily causally related to paracetamol.
Most reports of adverse reactions to paracetamol relate to overdose with the drug.
Chronic hepatic necrosis has been reported in a patient who took daily therapeutic doses of paracetamol for about a year and liver damage has been reported after daily ingestion of excessive amounts for shorter periods. A review of a group of patients with chronic active hepatitis failed to reveal differences in the abnormalities of liver function in those who were long-term users of paracetamol nor was the control of their disease improved after paracetamol withdrawal.
Nephrotoxicity following therapeutic doses of paracetamol is uncommon, but papillary necrosis has been reported after prolonged administration.
Low level transaminase elevations may occur in some patients taking therapeutic doses of paracetamol; these are not accompanied with liver failure and usually resolve with continued therapy or discontinuation of paracetamol.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard
The information provided in of Depon
is based on data of another medicine with exactly the same composition as the Depon.
. Be careful and be sure to specify the information on the section in the instructions to the drug Depon directly from the package or from the pharmacist at the pharmacy.
more…
Pills; Rectal suppositories; Rectal suppositories for children; Solution for infusion; Substance; Substance-powder; Syrup; Tablets, effervescent
Bolus; Coated tablet; Effervescent tablet; Film-coated tablet; Tablets, soluble
Suspension for ingestion for children
Liver damage is possible in adults who have taken 10g or more of Depon. Ingestion of 5g or more of Depon may lead to liver damage if the patient has risk factors (see below).
Risk Factors
If the patient
a) Is on long term treatment with carbamazepine, phenobarbitone, phenytoin, primidone, rifampicin, St John’s Wort or other drugs that induce liver enzymes.
Or
b) Regularly consumes ethanol in excess of recommended amounts.
Or
c) Is likely to be glutathione deplete e.g. eating disorders, cystic fibrosis, HIV infection, starvation, cachexia.
Symptoms
Symptoms of Depon overdosage in the first 24 hours are pallor, nausea, vomiting, anorexia and abdominal pain. Liver damage may become apparent 12 to 48 hours after ingestion. Abnormalities of glucose metabolism and metabolic acidosis may occur. In severe poisoning, hepatic failure may progress to encephalopathy, haemorrhage, hypoglycaemia, cerebral oedema, and death. Acute renal failure with acute tubular necrosis, strongly suggested by loin pain, haematuria and proteinuria, may develop even in the absence of severe liver damage. Cardiac arrhythmias and pancreatitis have been reported.
Management
Immediate treatment is essential in the management of Depon overdose. Despite a lack of significant early symptoms, patients should be referred to hospital urgently for immediate medical attention. Symptoms may be limited to nausea or vomiting and may not reflect the severity of overdose or the risk of organ damage. Management should be in accordance with established treatment guidelines, see BNF overdose section.
Treatment with activated charcoal should be considered if the overdose has been taken within 1 hour. Plasma Depon concentration should be measured at 4 hours or later after ingestion (earlier concentrations are unreliable).
Treatment with N-acetylcysteine may be used up to 24 hours after ingestion of Depon however, the maximum protective effect is obtained up to 8 hours post ingestion.
If required the patient should be given intravenous-N-acetylcysteine, in line with the established dosage schedule. If vomiting is not a problem, oral methionine may be a suitable alternative for remote areas, outside hospital.
Management of patients who present with serious hepatic dysfunction beyond 24 hours from ingestion should be discussed with the NPIS or a liver unit.
Liver damage is possible in adults who have taken 10g or more of paracetamol. Ingestion of 5g or more of paracetamol may lead to liver damage if the patient has risk factors (see below).
Risk factors
If the patient
a, Is on long term treatment with carbamazepine, phenobarbitone, phenytoin, primidone, rifampicin, St John’s Wort or other drugs that induce liver enzymes.
Or
b, Regularly consumes ethanol in excess of recommended amounts.
Or
c, Is likely to be glutathione deplete e.g. eating disorders, cystic fibrosis, HIV infection, starvation, cachexia.
Symptoms
Symptoms of paracetamol overdosage in the first 24 hours are pallor, nausea, vomiting, anorexia and abdominal pain. Liver damage may become apparent 12 to 48 hours after ingestion. Abnormalities of glucose metabolism and metabolic acidosis may occur. In severe poisoning, hepatic failure may progress to encephalopathy, haemorrhage, hypoglycaemia, cerebral oedema, and death. Acute renal failure with acute tubular necrosis, strongly suggested by loin pain, haematuria and proteinuria, may develop even in the absence of severe liver damage. Cardiac arrhythmias and pancreatitis have been reported.
Management
Immediate treatment is essential in the management of paracetamol overdose. Despite a lack of significant early symptoms, patients should be referred to hospital urgently for immediate medical attention. Symptoms may be limited to nausea or vomiting and may not reflect the severity of overdose or the risk of organ damage. Management should be in accordance with established treatment guidelines, see BNF overdose section.
Treatment with activated charcoal should be considered if the overdose has been taken within 1 hour. Plasma paracetamol concentration should be measured at 4 hours or later after ingestion (earlier concentrations are unreliable). Treatment with N-acetylcysteine may be used up to 24 hours after ingestion of paracetamol, however, the maximum protective effect is obtained up to 8 hours post-ingestion. The effectiveness of the antidote declines sharply after this time. If required the patient should be given intravenous N-acetylcysteine, in line with the established dosage schedule. If vomiting is not a problem, oral methionine may be a suitable alternative for remote areas, outside hospital. Management of patients who present with serious hepatic dysfunction beyond 24h from ingestion should be discussed with the NPIS or a liver unit.
High doses of sodium bicarbonate may be expected to induce gastrointestinal symptoms including belching and nausea. In addition, high doses of sodium bicarbonate may cause hypernatraemia; electrolytes should be monitored and patients managed accordingly.
Liver damage is possible in adults who have taken 10g or more of paracetamol. Ingestion of 5g or more of paracetamol may lead to liver damage if the patient has risk factors (see below)
Risk Factors:
If the patient
a) Is on long term treatment with carbamazepine, phenobarbitone, phenytoin, primidone, rifampicin, St John’s Wort or other drugs that induce liver enzymes
OR
b) Regularly consumes ethanol in excess of recommended amounts
OR
c) Is likely to be glutathione deplete e.g, eating disorders, cystic fibrosis, HIV infection, starvation, cachexia
Symptoms
Symptoms of paracetamol overdosage in the first 24 hours are pallor, nausea, hyperhidrosis, malaise, vomiting, anorexia, and abdominal pain. Liver damage may become apparent 12 to 48 hours after ingestion. This may include hepatomegaly, liver tenderness, jaundice, acute hepatic failure and hepatic necrosis. Abnormalities of glucose metabolism and metabolic acidosis may occur. Blood bilirubin, hepatic enzymes, INR, prothrombin time, blood phosphate and blood lactate may be increased. In severe poisoning, hepatic failure may progress to encephalopathy, haemorrhage, hypoglycaemia, cerebral oedema and death. Acute renal failure with acute tubular necrosis, strongly suggested by loin pain, haematuria and proteinuria, may develop even in the absence of severe liver damage. Cardiac arrhythmias and pancreatitis have been reported.
Management
Immediate treatment is essential in the management of paracetamol overdose. Despite a lack of significant early symptoms, patients should be referred to hospital urgently for immediate medical attention. Symptoms may be limited to nausea or vomiting and may not reflect the severity of the overdose or the risk of organ damage. Management should be in accordance with established treatment guidelines, see BNF overdose section.
Treatment with activated charcoal should be considered if the overdose has been taken within 1 hour. Plasma paracetamol concentrations should be measured at 4 hours or later after ingestion (earlier concentrations are unreliable). Treatment with N-acetylcysteine may be used up to 24 hours after ingestion of paracetamol, however the maximum protective effect is obtained up to 8 hours post-ingestion. The effectiveness of the antidote declines sharply after this time. If required the patient should be given intravenous N-acetylcysteine, in line with the established dosage schedule. If vomiting is not a problem oral methionine may be a suitable alternative for remote areas, outside hospital. Management of patient who present with serious hepatic dysfunction beyond 24h from ingestion should be discussed with the NPIS or a liver unit.
The information provided in of Depon
is based on data of another medicine with exactly the same composition as the Depon.
. Be careful and be sure to specify the information on the section in the instructions to the drug Depon directly from the package or from the pharmacist at the pharmacy.
more…
Pills; Rectal suppositories; Rectal suppositories for children; Solution for infusion; Substance; Substance-powder; Syrup; Tablets, effervescent
Bolus; Coated tablet; Effervescent tablet; Film-coated tablet; Tablets, soluble
Suspension for ingestion for children
Mechanisms of Action/Effect
Analgesic — the mechanism of analgesic action has not been fully determined. Depon may act predominantly by inhibiting prostaglandin synthesis in the central nervous system (CNS) and to a lesser extent, through a peripheral action by blocking pain-impulse generation.
The peripheral action may also be due to inhibition of prostaglandin synthesis or to inhibition of the synthesis or actions of other substances that sensitise pain receptors to mechanical or chemical stimulation.
Antipyretic — Depon probably produces antipyresis by acting centrally on the hypothalamic heat-regulation centre to produce peripheral vasodilation resulting in increased blood flow through the skin, sweating and heat loss. The central action probably involves inhibition of prostaglandin synthesis in the hypothalamus.
ATC Code N02B E01
Paracetamol has analgesic and antipyretic actions. The mechanism of action is based on the inhibition of prostaglandin biosynthesis.
Paracetamol is poorly absorbed in the stomach but well absorbed in the small intestine due to the greater surface area and hence adsorptive capacity.
Sodium bicarbonate is an excipient in the formulation which has a role in increasing the rates of gastric emptying and of paracetamol dissolution and hence the speed of absorption of paracetamol to provide faster onset of relief.
The amount of sodium bicarbonate contained in 2 tablets of Depon ActiFast are required per dose to have such effects. Sodium bicarbonate influences the rate of gastric emptying in a concentration dependant manner with the maximal effect achieved at near isotonic concentrations (150 mmol/litre)(i.e. 150 millimolar) — equivalent to 2 Depon ActiFast tablets in 100 ml water.
Hypertonic solutions (500-1,000 mmol/litre)(i.e. 500 to 1,000 millimolar — equivalent to the amount of sodium bicarbonate in 6-12 Depon ActiFast tablets given with 100 ml water) appear to inhibit gastric emptying. The therapeutic application of enhanced gastric emptying has previously been demonstrated with significantly faster rate of absorption of paracetamol and significantly faster onset of pain relief from soluble tablets containing sodium bicarbonate compared to conventional tablets. Depon ActiFast has been formulated with 630 mg sodium bicarbonate per tablet that results in near isotonicity at a 2-tablet dose in gastric fluid.
The role of the dissolution rate of Depon ActiFast Tablets in vivo at gastric pH is unknown. Therefore the role of tablet dissolution in the speed of action of Depon ActiFast Tablets is unclear.
It is likely that no single mode of action is responsible for the pharmacokinetic profile observed with Depon ActiFast. The relative contributions of the different factors will vary depending on the circumstances under which the product is taken.
Pharmacotherapeutic group: Other Analgesics and Antipyretics (Anilides)
ATC Code: N02 BE01
Paracetamol has analgesic and antipyretic effects similar to those of aspirin and is useful in the treatment of mild to moderate pain. It has only weak anti-inflammatory effects.
The information provided in of Depon
is based on data of another medicine with exactly the same composition as the Depon.
. Be careful and be sure to specify the information on the section in the instructions to the drug Depon directly from the package or from the pharmacist at the pharmacy.
more…
Pills; Rectal suppositories; Rectal suppositories for children; Solution for infusion; Substance; Substance-powder; Syrup; Tablets, effervescent
Bolus; Coated tablet; Effervescent tablet; Film-coated tablet; Tablets, soluble
Suspension for ingestion for children
Absorption and Fate
Depon is readily absorbed from the gastro-intestinal tract with peak plasma concentrations occurring about 30 minutes to 2 hours after ingestion. It is metabolised in the liver and excreted in the urine mainly as the glucuronide and sulfate conjugates. Less than 5% is excreted as unchanged Depon. The elimination half-life varies from about 1 to 4 hours. Plasma-protein binding is negligible at usual therapeutic concentrations but increases with increasing concentrations.
A minor hydroxylated metabolite which is usually produced in very small amounts by mixed-function oxidases in the liver and which is usually detoxified by conjugation with liver glutathione may accumulate following Depon overdosage and cause liver damage.
Paracetamol is rapidly and almost completely absorbed from the gastrointestinal tract. It is metabolised in the liver and excreted in the urine as the glucuronide and sulphate conjugates, — less than 5% is excreted unchanged in the urine as unmodified paracetamol. Binding to plasma proteins is minimal.
The mean elimination half-life of paracetamol following administration of Depon ActiFast is 2 to 3 hours and is similar to that achieved following administration of standard paracetamol tablets in fasted and fed states.
Following administration of Depon ActiFast, paracetamol has a median time to peak plasma concentrations (tmax) of 25 minutes in fasted subjects and 45 minutes in the fed subjects. Maximum plasma concentrations were reached at least twice as fast for Depon ActiFast as for standard paracetamol tablets in both the fed and fasted state (p= 0.0002). Following administration of Depon ActiFast, paracetamol is generally measurable in plasma within 10 minutes in both the fed and fasted state.
Two tablets of Depon ActiFast are required to be taken with 100 ml of water to obtain this fast rate of absorption of paracetamol. The maximum rate of absorption is obtained on an empty stomach. When one tablet is taken the rate of absorption of paracetamol for Depon ActiFast is the same as for standard paracetamol tablets. This is thought to be due to insufficient sodium bicarbonate present in the single tablet dose to increase the rate of paracetamol absorption. In addition, tablets taken with insufficient (<100 mls) water are unlikely to have increased speed of action. (See 5.1 Pharmacodynamic properties).
The extent of absorption of paracetamol from Depon ActiFast tablets is equivalent to that of standard paracetamol tablets as shown by AUC in both fed and fasted states.
Absorption
Paracetamol is rapidly and almost completely absorbed from the gastrointestinal tract. Peak plasma concentrations are reached 30-90 minutes post dose and the plasma half-life is in the range of 1 to 3 hours after therapeutic doses.
Distribution
Drug is widely distributed throughout most body fluids.
Biotransformation
Metabolism occurs almost entirely via hepatic conjugation with glucuronic acid (about 60%), sulphuric acid (about 35%) or cysteine (about 3%). Small amounts of hydroxylated and deacetylated metabolites have also been detected.
Children have less capacity for glucuronidation of the drug than do adults.
In overdosage there is increased N-hydroxylation followed by glutathione conjugation. When the latter is exhausted, reaction with hepatic proteins is increased leading to necrosis.
Elimination
Following therapeutic doses 90-100% of the drug is recovered in the urine within 24 hours.
Pharmacotherapeutic group
The information provided in Pharmacotherapeutic group of Depon
is based on data of another medicine with exactly the same composition as the Depon.
. Be careful and be sure to specify the information on the section Pharmacotherapeutic group in the instructions to the drug Depon directly from the package or from the pharmacist at the pharmacy.
more…
Other Analgesics and Antipyretics (Anilides)
Preclinical safety data
The information provided in Preclinical safety data of Depon
is based on data of another medicine with exactly the same composition as the Depon.
. Be careful and be sure to specify the information on the section Preclinical safety data in the instructions to the drug Depon directly from the package or from the pharmacist at the pharmacy.
more…
Pills; Rectal suppositories; Rectal suppositories for children; Solution for infusion; Substance; Substance-powder; Syrup; Tablets, effervescent
Bolus; Coated tablet; Effervescent tablet; Film-coated tablet; Tablets, soluble
Suspension for ingestion for children
None stated
Preclinical safety data on paracetamol in the literature have not revealed any findings which are of relevance to the recommended dosage and use of the product and which have not been mentioned in other sections of the SmPC.
Mutagenicity
There are no studies relating to the mutagenic potential of Depon Infant Sugar Free Colour Free 120 mg/5 ml Oral Suspension.
In vivo mutagenicity tests of paracetamol in mammals are limited and show conflicting results. Therefore, there is insufficient information to determine whether paracetamol poses a mutagenic risk to man.
Paracetamol has been found to be non-mutagenic in bacterial mutagenicity assays, although a clear clastogenic effect has been observed in mammalian cells in vitro following exposure to paracetamol (3 and 10 mM for 2h).
Carcinogenicity
There are no studies to the carcinogenic potential of Depon Infant Sugar Free Colour Free 120 mg/5 ml Oral Suspension.
There is inadequate evidence to determine the carcinogenic potential of paracetamol in humans. A positive association between the use of paracetamol and cancer of the ureter (but not of other sites in the urinary tract) was observed in a case-control study in which approximate lifetime consumption of paracetamol (whether acute or chronic) was estimated. However, other similar studies have failed to demonstrate a statistically significant association between paracetamol and cancer of the urinary tract, or paracetamol and renal cell carcinoma.
There is limited evidence for the carcinogenicity of paracetamol in experimental animals. Liver cell tumours can be detected in rats following chronic feeding of 500 mg/kg/day paracetamol.
Teratogenicity
There is no information relating to the teratogenic potential of Depon Infant Sugar Free Colour Free 120 mg/5 ml Oral Suspension. In humans, paracetamol crosses the placenta and attains concentrations in the foetal circulation similar to those in the maternal circulation. Intermittent maternal ingestion of therapeutic doses of paracetamol are not associated with teratogenic effects in humans.
Paracetamol has been found to be foetotoxic to cultured rat embryo.
Fertility
A significant decrease in testicular weight was observed when male Sprague-Dawley rats were given daily high doses of paracetamol (500 mg/kg/body weight/day) orally for 70 days.
Incompatibilities
The information provided in Incompatibilities of Depon
is based on data of another medicine with exactly the same composition as the Depon.
. Be careful and be sure to specify the information on the section Incompatibilities in the instructions to the drug Depon directly from the package or from the pharmacist at the pharmacy.
more…
None known
Special precautions for disposal and other handling
The information provided in Special precautions for disposal and other handling of Depon
is based on data of another medicine with exactly the same composition as the Depon.
. Be careful and be sure to specify the information on the section Special precautions for disposal and other handling in the instructions to the drug Depon directly from the package or from the pharmacist at the pharmacy.
more…
No special requirements for disposal.
Depon price
We have no data on the cost of the drug.
However, we will provide data for each active ingredient
The approximate cost of Acetaminophen 500 mg per unit in online pharmacies is from 0.16$ to 0.31$, per package is from 21$ to 31$.
The approximate cost of Acetaminophen 120 mg per unit in online pharmacies is from 2.05$ to 2.05$, per package is from 25$ to 25$.
The approximate cost of Acetaminophen 325 mg per unit in online pharmacies is from 0.21$ to 0.21$, per package is from 21$ to 21$.
The approximate cost of Acetaminophen 650 mg per unit in online pharmacies is from 2.3$ to 2.3$, per package is from 28$ to 28$.
Available in countries
Find in a country:
| Trade Name | Depon |
| Availability | Rx and/or OTC |
| Generic | Acetaminophen |
| Acetaminophen Other Names | Acenol, Acetaminofén, Acetaminophen, Acétaminophène, APAP, Paracetamol, Paracétamol, Paracetamolum |
| Related Drugs | Buprenex, aspirin, ibuprofen, tramadol, cyclobenzaprine, Paracetamol, naproxen, diclofenac, Tylenol, oxycodone |
| Type | |
| Formula | C8H9NO2 |
| Weight | Average: 151.1626 Monoisotopic: 151.063328537 |
| Protein binding |
The binding of acetaminophen to plasma proteins is low (ranging from 10% to 25%), when given at therapeutic doses. |
| Groups | Approved |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | Cyprus, Greece |
| Last Updated: | September 19, 2023 at 7:00 am |
Depon
Depon (paracetamol), also commonly known as Tylenol, is the most commonly taken analgesic worldwide and is recommended as first-line therapy in pain conditions by the World Health Organization (WHO). It is also used for its antipyretic effects, helping to reduce fever. This drug was initially approved by the U.S. FDA in 1951 and is available in a variety of forms including syrup form, regular tablets, effervescent tablets, injection, suppository, and other forms.
Depon is often found combined with other drugs in more than 600 over the counter (OTC) allergy medications, cold medications, sleep medications, pain relievers, and other products. Confusion about dosing of this drug may be caused by the availability of different formulas, strengths, and dosage instructions for children of different ages. Due to the possibility of fatal overdose and liver failure associated with the incorrect use of acetaminophen, it is important to follow current and available national and manufacturer dosing guidelines while this drug is taken or prescribed.
Animal and clinical studies have determined that acetaminophen has both antipyretic and analgesic effects. This drug has been shown to lack anti-inflammatory effects. As opposed to the salicylate drug class, acetaminophen does not disrupt tubular secretion of uric acid and does not affect acid-base balance if taken at the recommended doses. Depon does not disrupt hemostasis and does not have inhibitory activities against platelet aggregation. Allergic reactions are rare occurrences following acetaminophen use.
Uses
Depon is an analgesic drug used alone or in combination with opioids for pain management, and as an antipyretic agent.
In general, acetaminophen is used for the treatment of mild to moderate pain and reduction of fever. It is available over the counter in various forms, the most common being oral forms.
Depon injection is indicated for the management of mild to moderate pain, the management of moderate to severe pain with adjunctive opioid analgesics, and the reduction of fever.
Because of its low risk of causing allergic reactions, this drug can be administered in patients who are intolerant to salicylates and those with allergic tendencies, including bronchial asthmatics. Specific dosing guidelines should be followed when administering acetaminophen to children.
Depon is also used to associated treatment for these conditions:
Acute Gouty Arthritis, Acute Musculoskeletal Pain, Allergies, Ankylosing Spondylitis (AS), Arthritis, Chills, Cold, Cold Symptoms, Common Cold, Common Cold/Flu, Cough, Cough caused by Common Cold, Coughing caused by Flu caused by Influenza, Dyskinesia of the Biliary Tract, Dyskinesia of the Urinary Tract, Febrile Convulsions, Febrile Illness Acute, Fever, Fibromyalgia Syndrome, Flu caused by Influenza, Headache, Joint dislocations, Menstrual Distress (Dysmenorrhea), Mild pain, Muscle Inflammation, Muscle Injuries, Muscle Spasms, Musculoskeletal Pain, Nasal Congestion, Neuralgia, Osteoarthritis (OA), Pain, Pollen Allergy, Postoperative pain, Premenstrual cramps, Rheumatoid Arthritis, Rhinopharyngitis, Rhinorrhoea, Severe Pain, Sinusitis, Soreness, Muscle, Spasms, Spastic Pain of the Gastrointestinal Tract, Sprains, Tension Headache, Toothache, Upper Respiratory Tract Infection, Whiplash Syndrome, Acute Torticollis, Mild to moderate pain, Minor aches and pains, Minor pain, Moderate Pain, Airway secretion clearance therapy, Antispasmodic, Bronchodilation
How Depon works
According to its FDA labeling, acetaminophen’s exact mechanism of action has not been fully established — despite this, it is often categorized alongside NSAIDs (nonsteroidal anti-inflammatory drugs) due to its ability to inhibit the cyclooxygenase (COX) pathways. It is thought to exert central actions which ultimately lead to the alleviation of pain symptoms.
One theory is that acetaminophen increases the pain threshold by inhibiting two isoforms of cyclooxygenase, COX-1 and COX-2, which are involved in prostaglandin (PG) synthesis. Prostaglandins are responsible for eliciting pain sensations. Depon does not inhibit cyclooxygenase in peripheral tissues and, therefore, has no peripheral anti-inflammatory effects. Though acetylsalicylic acid (aspirin) is an irreversible inhibitor of COX and directly blocks the active site of this enzyme, studies have shown that acetaminophen (paracetamol) blocks COX indirectly. Studies also suggest that acetaminophen selectively blocks a variant type of the COX enzyme that is unique from the known variants COX-1 and COX-2. This enzyme has been referred to as COX-3. The antipyretic actions of acetaminophen are likely attributed to direct action on heat-regulating centers in the brain, resulting in peripheral vasodilation, sweating, and loss of body heat. The exact mechanism of action of this drug is not fully understood at this time, but future research may contribute to deeper knowledge.
Depon
Table Of contents
- Depon
- Uses
- Dosage
- Side Effect
- Precautions
- Interactions
- Uses during Pregnancy
- Uses during Breastfeeding
- Accute Overdose
- Food Interaction
- Half Life
- Volume of Distribution
- Clearance
- Interaction With other Medicine
- Contradiction
- Storage
Toxicity
LD50 = 338 mg/kg (oral, mouse); LD50 = 1944 mg/kg (oral, rat)
Overdose and liver toxicity
Depon overdose may be manifested by renal tubular necrosis, hypoglycemic coma, and thrombocytopenia. Sometimes, liver necrosis can occur as well as liver failure. Death and the requirement of a liver transplant may also occur. Metabolism by the CYP2E1 pathway releases a toxic acetaminophen metabolite known as N-acetyl-p-benzoquinoneimine(NAPQI). The toxic effects caused by this drug are attributed to NAPQI, not acetaminophen alone.
Carcinogenesis
Long-term studies in mice and rats have been completed by the National Toxicology Program to study the carcinogenic risk of acetaminophen. In 2-year feeding studies, F344/N rats and B6C3F1 mice consumed a diet containing acetaminophen up to 6,000 ppm. Female rats showed evidence of carcinogenic activity demonstrated by a higher incidence of mononuclear cell leukemia at doses 0.8 times the maximum human daily dose (MHDD). No evidence of carcinogenesis in male rats (0.7 times) or mice (1.2 to 1.4 times the MHDD) was noted. The clinical relevance of this finding in humans is unknown.
Mutagenesis
Depon was not found to be mutagenic in the bacterial reverse mutation assay (Ames test). Despite this finding, acetaminophen tested positive in the in vitro mouse lymphoma assay as well as the in vitro chromosomal aberration assay using human lymphocytes. In published studies, acetaminophen has been reported to be clastogenic (disrupting chromosomes) when given a high dose of 1,500 mg/kg/day to the rat model (3.6 times the MHDD). No clastogenicity was observed at a dose of 750 mg/kg/day (1.8 times the MHDD), indicating that this drug has a threshold before it may cause mutagenesis. The clinical relevance of this finding in humans is unknown.
Impairment of Fertility
In studies conducted by the National Toxicology Program, fertility assessments have been performed in Swiss mice in a continuous breeding study. No effects on fertility were seen.
Use in pregnancy and nursing
The FDA label for acetaminophen considers it a pregnancy category C drug, meaning this drug has demonstrated adverse effects in animal studies. No human clinical studies in pregnancy have been done to this date for intravenous acetaminophen. Use acetaminophen only when necessary during pregnancy. Epidemiological data on oral acetaminophen use in pregnant women demonstrate no increase in the risk of major congenital malformations. While prospective clinical studies examining the results of nursing with acetaminophen use have not been conducted, acetaminophen is found secreted in human milk at low concentrations after oral administration. Data from more than 15 nursing mothers taking acetaminophen was obtained, and the calculated daily dose of acetaminophen that reaches the infant is about 1 to 2% of the maternal dose. Caution should be observed when acetaminophen is taken by a nursing woman.
Food Interaction
- Avoid alcohol. Alcohol may increase the risk of hepatotoxicity.
- Take with or without food. The absorption is unaffected by food.
Depon Alcohol interaction
[Major] GENERALLY AVOID:
Chronic, excessive consumption of alcohol may increase the risk of acetaminophen-induced hepatotoxicity, which has included rare cases of fatal hepatitis and frank hepatic failure requiring liver transplantation.
The proposed mechanism is induction of hepatic microsomal enzymes during chronic alcohol use, which may result in accelerated metabolism of acetaminophen and increased production of potentially hepatotoxic metabolites.
In general, chronic alcoholics should avoid regular or excessive use of acetaminophen.
Alternative analgesic/antipyretic therapy may be appropriate in patients who consume three or more alcoholic drinks per day.
However, if acetaminophen is used, these patients should be cautioned not to exceed the recommended dosage (maximum 4 g/day in adults and children 12 years of age or older).
Depon Drug Interaction
Unknown: aspirin, aspirin, diphenhydramine, diphenhydramine, omega-3 polyunsaturated fatty acids, omega-3 polyunsaturated fatty acids, fluticasone nasal, fluticasone nasal, metoprolol, metoprolol, polyethylene glycol 3350, polyethylene glycol 3350, cyanocobalamin, cyanocobalamin, ascorbic acid, ascorbic acid, cholecalciferol, cholecalciferol, cetirizine, cetirizine
Volume of Distribution
Volume of distribution is about 0.9L/kg. 10 to 20% of the drug is bound to red blood cells. Depon appears to be widely distributed throughout most body tissues except in fat.
Elimination Route
Depon has 88% oral bioavailability and reaches its highest plasma concentration 90 minutes after ingestion.
Peak blood levels of free acetaminophen are not reached until 3 hours after rectal administration of the suppository form of acetaminophen and the peak blood concentration is approximately 50% of the observed concentration after the ingestion of an equivalent oral dose (10-20 mcg/mL).
The percentage of a systemically absorbed rectal dose of acetaminophen is inconsistent, demonstrated by major differences in the bioavailability of acetaminophen after a dose administered rectally. Higher rectal doses or an increased frequency of administration may be used to attain blood concentrations of acetaminophen similar to those attained after oral acetaminophen administration.
Half Life
The half-life for adults is 2.5 h after an intravenous dose of 15 mg/kg. After an overdose, the half-life can range from 4 to 8 hours depending on the severity of injury to the liver, as it heavily metabolizes acetaminophen.
Clearance
Adults: 0.27 L/h/kg following a 15 mg/kg intravenous (IV) dose.
Children: 0.34 L/h/kg following a 15 mg/kg intravenous (IV dose).
Elimination Route
Depon metabolites are mainly excreted in the urine. Less than 5% is excreted in the urine as free (unconjugated) acetaminophen and at least 90% of the administered dose is excreted within 24 hours.
Innovators Monograph
You find simplified version here Depon
FAQ
What is Depon used for?
Depon is used to relieve mild to moderate pain from headaches, muscle aches, menstrual periods, colds and sore throats, toothaches, backaches, and reactions to vaccinations (shots), and to reduce fever.
How safe is Depon?
When used as directed, taking Depon is generally safe and effective.
How does Depon work?
Depon relieves pain by elevating the pain threshold, that is, by requiring a greater amount of pain to develop before a person feels it. It reduces fever through its action on the heat-regulating center of the brain.
What are the common side effects of Depon?
Common side effects of Depon are include;
- nausea,
- stomach pain,
- loss of appetite,
- itching,
- rash,
- headache,
- dark urine,
- clay-colored stools,
- or jaundice (yellowing of skin or eyes).
Is Depon safe during pregnancy?
Depon as one of the only safe pain relievers for pregnant individuals during pregnancy.
Is Depon safe during breastfeeding?
Depon are safe to use when breastfeeding.
Can I drink alcohol with Depon?
Mixing Depon and alcohol can potentially lead to liver damage. Rarely, liver damage can be severe or even life-threatening.
Can I drive after taking Depon?
You should know that this medication may make you drowsy. Do not drive a car or operate machinery until you know how this medication affects you. you should know that Depon and codeine may cause dizziness, lightheadedness, and fainting when you get up too quickly from a lying position.
How often can I take Depon?
Take every 4 to 6 hours, as needed, up to 4 times in a 24-hour period.
How do I take Depon?
Take Depon exactly as directed on the prescription or package label.
How much Depon can I take daily?
The usual dose is 325 mg to 650 mg. Take every 4 to 6 hours, as needed, up to 4 times in a 24-hour period. The maximum dose may vary from 3,000 mg to 4,000 mg, but do not take more than 4,000 mg in a 24-hour period.
How long does Depon take to work?
It usually takes about 45 minutes for oral, liquid, or tablet Depon to start working. The oral disintegrating tablets start to work in about 20 minutes.
What is the half life of Depon?
The Depon half-life was 5.4 hours (range, 0.8-119.7 hours).
How long can I take Depon?
Don’t take Depon for more than 10 days in a row unless you’ve been instructed to do so by your doctor.
Who should not take Depon?
You should not take Depon if you are allergic to it, or if you take other medications that contain acetaminophen. Ask a doctor or pharmacist if this medicine is safe to use if you’ve ever had cirrhosis of the liver, or if you drink alcohol daily.
What happens if I miss a dose?
Since Depon is taken as needed, you may not be on a dosing schedule. If you are taking the medication regularly, take the missed dose as soon as you remember. Skip the missed dose if it is almost time for your next scheduled dose. Do not take extra medicine to make up the missed dose.
What happens if I overdose?
Seek emergency medical attention. An overdose of acetaminophen can be fatal. The first signs of an Depon overdose include loss of appetite, nausea, vomiting, stomach pain, sweating, and confusion or weakness. Later symptoms may include pain in your upper stomach, dark urine, and yellowing of your skin or the whites of your eyes.
Should I stop taking Depon?
It is suggested that you stop taking Depon and talk with your doctor if: You still feel pain after 10 days (adult) or 5 days (children) You still have a fever after 3 days. Your symptoms get worse, or you feel new symptoms.
Can Depon affects my heart ?
It is not known to increase risks of heart attack, heart failure, or stroke.
Can Depon affect my kidneys?
Depon broken down/metabolized almost completely by the liver, so the kidneys hardly do any of the work and are not affected by it. Depon is safe for the kidneys.
Can Depon affects my liver?
Depon toxicity can quickly lead to liver damage. Liver damage associated with Depon use sends thousand of Americans to the hospital each year.
DEPON® and life goes ON!
DEPON® contains the active substance paracetamol, one of the most popular analgesic substances in the world, which is available without a prescription.
DEPON® is the top non-narcotic analgesic*.
Relieves from:
- Headaches
- Fever
- Menstrual pain
- Neuralgia
- Tooth pain
- Joint pain
- Muscle pain
DEPON® is available in various forms:
- DEPON® MAXIMUM: 1,000mg paracetamol for quick relief.
- DEPON® 500mg paracetamol tablet: The all-time-classic, easy-to-swallow DEPON tablet.
- DEPON® 500mg effervescent paracetamol tablet, non-flavoured.
- DEPON® VIT C: Covers the body’s increased need in vitamin C.
- DEPON® ODIS: The only orodispersible painkiller (disintegrates orally without water).
- DEPON® Syrup for children, cherry-flavoured.
- DEPON® 200mg and 600mg paracetamol suppositories for children and adults respectively, when other pharmaceutical forms are deemed unsuitable (e.g. due to gastrointestinal disorders).
*Source: IQVIA, MAT, October 2019
Do not take this medicine: if You are allergic (hypersensitive) to the active substance or any of the other ingredients, if you have severe liver or renal impairment, if you have kidney stones (only the effervescent form).
The content of this website is not and should not be interpreted as a substitute for medical advice, for which you should and are advised to consult your doctor or pharmacist.
THE MINISTRY OF HEALTH AND THE NATIONAL ORGANISATION FOR MEDICINES SUGGEST: READ THE PATIENT INFORMATION LEAFLET CAREFULLY. CONSULT YOUR DOCTOR OR PHARMACIST
×
Αυτός ο ιστότοπος χρησιμοποιεί cookies
Με τη χρήση αυτού του ιστότοπου, αποδέχεστε τους Όρους Χρήσης
Depon Drug Information [ Bristol-Myers Squibb ]
Table of content
Depon category:
- Human
- Analgetics Acetaminophen Salicylates Codeine
- Miscellaneous Analgesics and Antipyretics
Active ingredients:
- Acetaminophen
Depon companies and manufacturers:
-
Bristol-Myers Squibb
General Information
Depon forms, composition and dosages:
- N / A
Indications, usages and classification codes:
- N02BE01 — Acetaminophen (Paracetamol)
There is an additional general information about this medication active ingredient paracetamol (acetaminophen):
Pharmacological action
Analgesic-antipyretic. It has analgesic, antipyretic and weak anti-inflammatory action. The mechanism of action is associated with inhibition of prostaglandin synthesis, the predominant influence on the thermoregulation center in the hypothalamus, enhances heat transfer.
Why is Depon prescribed?
Pain weak and moderate intensity of different genesis (including headache, migraine, toothache, neuralgia, myalgia, algomenorrhea; pain in trauma, burns). Fever in infectious and inflammatory diseases.
Paracetamol dosage and administration
Oral or rectally adults and adolescents with a body weight over 60 kg is used in a single dose of 500 mg, the multiplicity of admission — up to 4 times / Maximum duration of treatment — 5-7 days.
Maximum dose: single — 1 g, daily — 4 g.
Single dose for oral administration for children aged 6-12 years — 250-500 mg, 1-5 years — 120-250 mg, from 3 months to 1 year — 60-120 mg, up to 3 months — 10 mg / kg. Single dose rectal in children aged 6-12 years — 250-500 mg, 1-5 years — 125-250 mg.
Multiplicity — 4 at intervals of not less than 4 h. The maximum duration of treatment — 3 days.
Maximum dose: 4 single dose per day.
Depon Side Effects
Digestive system: rarely — dyspepsia; long-term use at high doses — hepatotoxic effects, methemoglobinemia, renal dysfunction and liver, hypochromic anemia.
Hemopoietic system: rarely — thrombocytopenia, leukopenia, pancytopenia, neutropenia, agranulocytosis.
Allergic reactions: rarely — skin rash, itching, hives.
Contraindications
Chronic active alcoholism, increased sensitivity to paracetamol, marked disturbances of liver function and / or kidney disease, anemia, pregnancy (I term).
Using during pregnancy and breastfeeding
Paracetamol crosses the placental barrier. So far, no observed adverse effects of paracetamol on the fetus in humans.
Paracetamol is excreted in breast milk: the content in milk was 0.04-0.23% of the dose adopted mother.
If necessary, use of paracetamol during pregnancy and lactation (breastfeeding) should carefully weigh the potential benefits of therapy for the mother and the potential risk to the fetus or child.
In experimental studies found no embryotoxic, teratogenic and mutagenic action of paracetamol.
Special Instructions
With caution used in patients with disorders of the liver and kidneys, with benign hyperbilirubinemia, as well as in elderly patients.
With prolonged use of paracetamol is necessary to monitor patterns of peripheral blood and functional state of the liver.
Used for treatment of premenstrual tension syndrome in combination with pamabrom (diuretic, a derivative of xanthine) and mepyramine (Histamine H1-receptors blocker).
Depon Drug Interactions
With the simultaneous use with inducers of microsomal liver enzymes, means having hepatotoxic effect, increasing the risk of hepatotoxic action of paracetamol.
With the simultaneous use of anticoagulants may be slight to moderate increase in prothrombin time.
With the simultaneous use of anticholinergics may decrease absorption of paracetamol.
With the simultaneous use of oral contraceptives accelerated excretion of paracetamol from the body and may reduce its analgesic action.
With the simultaneous use with urological means reduced their effectiveness.
With the simultaneous use of activated charcoal reduced bioavailability of paracetamol.
When applied simultaneously with diazepam may decrease excretion of diazepam.
There have been reports about the possibility of enhancing mielodepression effect of zidovudine while applying with paracetamol. A case of severe toxic liver injury.
Described cases of toxic effects of paracetamol, while the use of isoniazid.
When applied simultaneously with carbamazepine, phenytoin, phenobarbital, primidonom decreases the effectiveness of paracetamol, which is caused by an increase in its metabolism and excretion from the body. Cases of hepatotoxicity, while the use of paracetamol and phenobarbital.
In applying cholestyramine a period of less than 1 h after administration of paracetamol may decrease of its absorption.
At simultaneous application with lamotrigine moderately increased excretion of lamotrigine from the body.
With the simultaneous use of metoclopramide may increase absorption of paracetamol and its increased concentration in blood plasma.
When applied simultaneously with probenecid may decrease clearance of paracetamol, with rifampicin, sulfinpyrazone — may increase clearance of paracetamol due to increasing its metabolism in the liver.
At simultaneous application with ethinylestradiol increases absorption of paracetamol from the gut.
Enhances the effect of indirect anticoagulants (coumarin derivatives and indandione). Antipyretic and analgesic activity of caffeine increases, reduce — rifampicin, phenobarbital and alcohol (accelerated biotransformation, inducing microsomal liver enzymes).
Depon in case of emergency / overdose
At a reception in toxic doses (10-15 g in adults) may develop liver necrosis.
Symptoms of overdose may include: nausea, vomiting, loss of appetite, sweating, extreme tiredness, unusual bleeding or bruising, pain in the upper right part of the stomach, yellowing of the skin or eyes, flu-like symptoms
Storage Conditions
In a dry, protected from light place, temperature 15-25 °C.
Expiration date for paracetamol: 3 years.
PLEASE, BE CAREFUL!
Be sure to consult your doctor before taking any medication!
- Depon analogs
- Depon similar
Форма выпуска, упаковка и состав
препарата Дипана®
Таблетки, покрытые оболочкой светло-зеленого цвета, продолговатые, двояковыпуклые, с закругленными концами, со специфическим запахом.
Вспомогательные вещества: крахмал кукурузный, целлюлоза микрокристаллическая, магния гидроксосиликат, магния стеарат, натрия карбоксиметилкрахмал, натрия кроскармеллоза, натрия лаурилсульфат, натрия метилпарагидроксибензоат, натрия пропилпарагидроксибензоат, натрия бензоат, бронопол.
Состав оболочки: пленочное покрытие Instacoat IC-S-2372 (гипромеллоза, макрогол, магния гидросиликат, титана диоксид, краситель хинолин желтый, краситель бриллиантовый голубой), покрытие Instacoat IC-S-344 (гипромеллоза, диэтилфталат, этилцеллюлоза).
12 шт. — блистеры (4) — пачки картонные.
90 шт. — банки пластиковые (1) — пачки картонные.
Фармакологическое действие
Гепатопротектор растительного происхождения. Представляет собой комплекс биологически активных веществ растительного происхождения, предохраняющих печень от воздействия токсичных веществ (алкоголь, лекарственные препараты), стимулирует регенерацию клеток печени; нормализует белковосинтетическую функцию печени; способствует улучшению процесса пищеварения.
Дипана содержит сухие водные экстракты растений, обладающие следующим действием.
Экстракты корневищ пикроризы курроа, листьев и цветов андрографиса метельчатого обладают гепатопротекторным действием, предотвращая поражение печени токсическими веществами и лекарственными средствами.
Экстракт листьев и плодов паслена черного активизирует детоксикационную функцию печени, оказывая стимулирующее влияние на ферментные системы митохондрий гепатоцитов.
Экстракт листьев иссопа водного, корней и листьев эклипты белой обладают антиоксидантными свойствами, улучшают общее самочувствие пациентов.
Экстракт корней бурхавии раскидистой улучшает отток желчи.
Экстракты корней и листьев филлантуса нирури и стеблей тиноспоры сердцелистной обладают иммуномодулирующей активностью.
Экстракт корневищ имбиря лекарственного уменьшает диспепсию, нормализует перистальтику кишечника и желчевыводящих протоков.
Экстракт плодов перца длинного предотвращает развитие фиброза печени, потенцирует терапевтическое действие компонентов, входящих в состав остальных экстрактов.
Фармакокинетика
Действие препарата Дипана является результатом совокупного действия его компонентов, поэтому проведение кинетических наблюдений не представляется возможным; все вместе компоненты не могут быть прослежены с помощью маркеров или биоисследований. По этой же причине невозможно обнаружить и метаболиты препарата.
Показания препарата
Дипана®
- острые и хронические инфекционные, токсические и лекарственные гепатиты;
- алкогольная болезнь печени;
- жировая дистрофия печени различной этиологии;
- цирроз печени;
- профилактика поражения печени при хронических интоксикациях (в т.ч. при длительном употреблении алкоголя).
Режим дозирования
Таблетки следует принимать внутрь, до приема пищи, запивая достаточным количеством воды.
В качестве монотерапии при алкогольной болезни или жировой дегенерации печени средняя рекомендуемая доза составляет 2-3 таб. ( в зависимости от тяжести патологии) 2 раза/сут в течение 8-12 недель.
В составе комплексной терапии гепатитов, при токсических и лекарственных поражениях, циррозе печени препарат назначают по 2 таб. 3 раза/сут в течение 4-8 недель.
Для профилактики поражений печени при хронических интоксикациях назначают по 1-2 таб. 3 раза/сут в течение 4-8 недель.
Побочное действие
Возможно: аллергические реакции.
В отдельных случаях: сухость во рту, тошнота, спазмы кишечника, диарея, нарушение сна, головные боли, усиление диуреза.
Противопоказания к применению
- период лактации (грудного вскармливания);
- беременность;
- повышенная чувствительность к компонентам препарата.
Применение при беременности и кормлении грудью
Препарат противопоказан к применению при беременности и в период лактации.
Особые указания
Из-за отсутствия опыта применения не рекомендуется назначение препарата детям младше 10 лет.
Передозировка
Данные по передозировке препарата Дипана не предоставлены.
Лекарственное взаимодействие
Лекарственное взаимодействие препарата Дипана не описано.
Условия хранения препарата Дипана®
Препарат следует хранить в сухом, защищенном от света, недоступном для детей месте при температуре не выше 25°C.
Срок годности препарата Дипана®
Условия реализации
Препарат отпускается по рецепту.